Bristol Myers says schizophrenia drug launch ‘off to a solid start’

Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates

Bristol Myers Squibb stock dropped Thursday, though the drugmaker beat first-quarter expectations and raised its outlook for the year. The post Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates appeared first on Investor's Business Daily.

Bristol Myers says schizophrenia drug launch ‘off to a solid start’

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily beating Wall Street expectations.

Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump's planned pharmaceutical tariffs.

Bristol Myers Squibb Reports First Quarter Financial Results for 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Apr 24, 2025-

Big drugmakers stood out on Thursday on a volatile day for corporate financial reports, beating analysts' expectations despite threats of possible industry-specific tariffs, efforts to lower drug prices and federal layoffs that could undermine planned investments in the U.S. in the coming years.

Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds - Pharmaceutical Technology

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.